Categories: Latest

Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency

USA, August 29, 2016: Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) announced today that the European Medicines Agency (EMA) has accepted for review Mylan’s Marketing Authorization Application (MAA) for a proposed biosimilar Trastuzumab, which is used to treat certain HER2-positive breast and gastric cancers. This is the second biosimilar submission developed by the partnership that has been accepted for review in Europe. Last month, Mylan’s MAA for the proposed biosimilar Pegfilgrastim was accepted for review by EMA.

Mylan and Biocon, which have co-developed this proposed biosimilar, anticipate that this may be the first MAA for a Trastuzumab biosimilar accepted by the EMA for review.

This filing includes analytical, functional and pre-clinical data, as well as results from the pharmacokinetics (PK) and confirmatory efficacy / safety global clinical trials for Trastuzumab. The PK study had demonstrated measured bioequivalence of Mylan’s and Biocon’s proposed Trastuzumab biosimilar relative to that of the reference drug. The second study, the ‘HERITAGE Study’, evaluated the efficacy, safety and immunogenicity of the proposed biosimilar Trastuzumab in comparison to branded Trastuzumab.

Mylan President Rajiv Malik commented: “The acceptance of our regulatory submission of our proposed biosimilar Trastuzumab in Europe is another example of the strong progress we continue to make across our broad biosimilars portfolio. Following our successful commercialization in India and emerging markets, we look forward to our pending launch in Europe. Europe represents a key market for more affordable versions of these important products, as governments across the region strive to reduce healthcare costs. We look forward to continuing to work to bring this product to patients upon approval.”

Arun Chandavarkar, CEO and Joint Managing Director, Biocon, said: “The regulatory submission for proposed biosimilar Trastuzumab in Europe takes us a step closer towards enabling affordable access to this critical biologic therapy for the treatment of HER2-positive breast cancer. We remain committed to bring a diversified portfolio of high-quality, life-enhancing biosimilars to patients globally.”

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

CARE Hospitals, Nampally, Hosts the 12th National Infection Prevention and Control (IPC) Certificate Program

Hyderabad, November 22, 2024: CARE Hospitals, Nampally, successfully hosted the 12th National Infection Prevention and Control (IPC)…

3 days ago

61-Year-Old African Doctor morbidly Obese successfully treated for End-Stage Renal Disease via Robot-Assisted Kidney Transplant at Fortis Hospital Cunningham Road

Bengaluru, November 22, 2024: Fortis Hospital, Cunningham Road successfully performed a life-enhancing robot-assisted kidney transplant on 61-year-old…

3 days ago

Lung Cancer Awareness Month

By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…

4 days ago

Unmasking COPD: The Silent Respiratory Threat of Smoking

By  Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital …

4 days ago

Khazi India Foundation to Host Expert Cardiac Consultations in Adoni

Kurnool, November 20, 2024: Adoni, Andhra Pradesh, – The Khazi India Foundation is pleased to…

5 days ago

Aakash Healthcare Celebrates Children’s Day with Kids from Choti Si Khushi

New Delhi, November 20, 2024: Aakash Healthcare marked this year’s Children’s Day with a joyful…

5 days ago